- People with Inflammatory Bowel Disease (IBD) have an increased Risk of Developing Parkinson’s Disease, a neurodegenerative condition.
- Disruption of the Gut Microbiome is a feature of that conditions, but experts do not know ifis gut dysbiosis underlies the link Between the Two Desense.
- A New Study comparing the Microbiomes of People withd and Parkinson’s Disease has found that People with Eithher Condition Have Delats in similar Types of Benefit Bacteria.
- The Findings suggest that therapies targeting the microbiome to reduces inflammation might reduces Parkinson’s Risk in People with Ibd.
Inflamatory Bowel Disease (IBD) AFFFETS AROUND 5 MILLION PEOPLE AROUND THE WORLD. It results in a number of gastrointestinal and other symptoms, which may be allegated by medications and dietary changes.
Several Studies have suggested that Ibd May increased to Perso’s Risk of Developing
GUT INFLAMMATION IS COMMON IN BOTH IBD AND PARKINSON’S DIEW. And experts Believe That One of the Factors in This Gut Inflammation is Dysbiosis, or Disruption of the Gut Microbiome – The Hage Population of Microorganisms That Live Live In the Gastrointestinal (GI) Tract.
A New Study Analyzing the Gut Microbiomes of People with Ibd and Parkinson’s Has Found That They Share Several Differences From The Microbiomes of Healthy People. Most Noticeable, People withd or Parkinson’s Had Greatly Depleted Numbers of Bacteria that produces short-chain fatty acids-Molecules that modulates the activity of the immune system.
The Research, By Scientists From The University of Florida, Is Published in
“This is an interesting study as it is the first time a direct comparison has been made Between the Gut Microbiome of People with Ibd and People With Parkinson’s.
– Katherine Fletcher, Research Communications Lead, Parkinson’s UK, Who Was Not Involved in the Study,
The Gut Microbiome’s Role in Ibd and Parkinson’s
Michael S. Okun, MD, Medical Advisor at The Parkinson’s Foundation and Director at The Norman Fixel Institute for Neurological Diseases AT UF Health, One of the Study Authors, Told Medical News Today:
“This Study Identified Potential Unique Features of the Human Parkinson’s and Inflamatory Bowel Disease Microbiome and Also used the gut ‘metagenomes’ to shed light on what may be going on in the gi tract.”
To identify whether the microbiome might help explanin epidemiological links Between the Two Diseases, they recruited 54 People withinson’s Disease, 26 Withd Ibd, and 16 Healthy Control Individuals. ALL WERE AGES BETWEEN 40 AND 80 YEARS, ALTHOUGH THOSE WITH PARKINSON’S WERE, ON Average, OLDER.
All Study Participants Providad Stool Samples for Analysis. The Refers identified the bacteria present in these stool samples using
Fewer Short-Chain Fatty Acid-Producting Bacteria in Parkinson’s, IBD
In People with Barkinson’s Disease and IBD, Several Prominent Short-Chain Fatty Acid-Producting Species were Depleted. They Also Had reduced scfa synthesis pathways.
“Deplets in Short-Chain Fatty Acid (SCFA) -Peria Bacteria was One of the Most Interesting Findings. Addionione That Will require Closer Look is the Deplets in Pathways Involved in the Synthesis of Acetate and Butyrat (2 scfas) in Both Parkinson’s and Inflammatory Bowel Disease.
– Michael S. Okun, MD
Many of the depleted bacteria are producers of butyrat, a scfa that is though to provide protection aga Instit neurodegeneration. In previous work, subject of the Same Researchers have shown that People with Higher Levels of Butyratrate in Their Stool have left Age of Onset of Parkinson’s, Suggesting that it May Help Protect Against The Disease.
Fletcher Highlightd Discovering the Depletion of these bacteria may be important:
“SCFA-BACTERIA DELEASE FACTORS THAT ARE ANTI-INFLAMMATORY, AND GUT INFLAMMATION IS SEEN IN BYBD IBD AND PD AND IS ASSOCIATED WITH AN INCREASED RISK OF PD. ONE OF THE FACTORS THAT SCFA-BACTERIA PRODUCE IS BUTYRATE WHICH PREVENTIC MODIFICATION OF THE GEES AND Been Associated with Neuroprotecction in Animals of Pd. “
Gut Dysbiosis May Be A Cause Or Concequence
Because this was an observational Study, It Cannot Determine Whether The Alterations in the Microbiomes of People withinson’s Disease and Ibd are causing the disease, or are a result of the condition.
The Suggest that inflammation may result in Dysbiotic Microbiome, Which Favurs Pathogenic Microbes That Are Uble to Tolerate More Extreme Assets. However, it is positive that the pathogenic bacteria cause the inflammation.
Possible Treatment Options for Parkinson’s and Ibd
Previous Research Has Found That Anti-Tnf Therapies, which are Commonly used to fight inflammation in ibd, May reduces The Risk of Developing Parkinson’s Disease. However, While their Study Supported the Role of Inflammation as a Risk Factor, Okun Urged Caution:
“The Data from This Study Should Not Become to Rationale for CliniciS to reflective treat already diagnosed or at-risk folks with anti-tnf therapies. You are Drugs Have Risks, and Although There May Be Future Clinical Trials, We Are Not There Yet.”
However, Fletcher Highlightd Research into the Effects of the Drugs in People With A similar condition:
“This Hypothesis is already being test clinically. People with a Sleep Disorder Called Rem Sleep Behavior Disorder (RBD), WHO has a see High Risk of Developing PD with 10 Years and Also An Alrtred Gut Microbiome Similar to PD, Are Being Being Tested With anti-tnf therapy to see whether it Slows download or prevents their conversion from rbd to pd. ”
WHILE OKUN ADVISED AGAINST THE WIDESPREAD USE OF PRE-PROBIOTICS ASS EFFECTS MAY HIGHLY DEPEND ON A PERSON’S GUT MICROBIOME, FLETCHER TOLD US THAT A HEALTHY DIET COULD BE HELPFUL. She emphasized that the Mediterranean Diet, which modifies gut bacteria in a beneficial way, is associated with a reduced Risk of Parkinson’s Disease.
“This Work Highlights The Importance of Being Uble to Pinpoint Changes in the Gut That Might Lead to Parkinson’s and Finding Ways To Intervene. The Results Also Show The Importance of Research into Diet and Supplements for Parkinson’s.”
– Katherine Fletcher
